sprite-preloader
Anzeige
Mehr »
Freitag, 22.02.2019 Börsentäglich über 12.000 News von 595 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
DoPropeller Health links up with Orion to expand its digital inhaler footprint in Europe
DoHow understanding organ growth in fruit flies sheds light on genetic diseases
DoEnzyvant finds new CEO in former Alexion executive Rachelle Jacques
DoMerck moves to buy Immune Design and its cancer vaccines platform for $300M
DoMPM Capital secures $400M treasure chest for early biotechs
DoMorphic bags J&J as second big pharma partner for oral integrins
DoQiagen links with Ares Genetics in push for new bioinformatics and assay solutions
DoWuXiAppTec CDMO STA Pharma inks exclusive deal with Swiss biotech BioLingus
MiClinerion and Citeline team to streamline and improve decisionmaking for trials
MiPfizer CNS spinout Cerevel brings on new CMO to launch phase 3 work in Parkinson's disease
MiUsing Bristol-Myers' popular leukemia drug to improve anti-PD-1 cancer immunotherapy
MiMedtronic launches 'brain pacemaker' implant for reducing epileptic seizures
MiTurbulent times for Xencor as FDA slaps hold on AML bispecific
MiIntuitive Surgical receives FDA clearance for its lung cancer biopsy robot
MiPluristem's cell therapies head for orbit with NASA deal
MiVical stops antifungal trial, lays off staff to eke out cash
MiMorphoSys CEO Simon Moroney announces his retirement
MiNovo Nordisk to make its digital insulin pens compatible with Abbott, Glooko and more
MiFDA clears Hygieia's 'GPS for insulin' diabetes management app
MiDarrin Disley takes CEO role at cell therapy startup
DiWith positive phase 3, Intercept to file NASH drug for approval while Inventiva faces a setback
DiPfizer and Lilly's NGF painkiller moves forward, meeting phase 3 endpoints in lower back pain
DiEnd of the line looms for Aradigm as it files for bankruptcy
DiArix reappoints CEO 5 months after starting hunt for replacement
DiRealm set to offload assets, leave London following failures